Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years.

Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years.

Pokaži ostale verzije (1)

Survival has improved in bladder cancer but few studies have considered extended periods or covered populations for which medical care is essentially free of charge. We analyzed survival in urothelial cancer (UC, of which vast majority are bladder cancers) in Finland and Sweden over a 50-year period...

Bibliografski detalji
Glavni autori:	Kari Hemminki, Asta Försti, Akseli Hemminki, Börje Ljungberg, Otto Hemminki
Format:	Članak
Jezik:	English
Izdano:	Public Library of Science (PLoS) 2022-01-01
Serija:	PLoS ONE
Online pristup:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0261124&type=printable

Slični predmeti

Survival in bladder and upper urinary tract cancers in Finland and Sweden through 50 years
od: Kari Hemminki, i dr.
Izdano: (2022-01-01)

Progress in survival in renal cell carcinoma through 50 years evaluated in Finland and Sweden.
od: Kari Hemminki, i dr.
Izdano: (2021-01-01)

Survival in colon and rectal cancers in Finland and Sweden through 50 years
od: Akseli Hemminki, i dr.
Izdano: (2021-10-01)

Incidence trends in bladder and lung cancers between Denmark, Finland and Sweden may implicate oral tobacco (snuff/snus) as a possible risk factor
od: Kari Hemminki, i dr.
Izdano: (2021-05-01)

Cervical, vaginal and vulvar cancer incidence and survival trends in Denmark, Finland, Norway and Sweden with implications to treatment
od: Kari Hemminki, i dr.
Izdano: (2022-04-01)

Incidence and survival in laryngeal and lung cancers in Finland and Sweden through a half century.
od: Anni Koskinen, i dr.
Izdano: (2022-01-01)

Bladder and upper urinary tract cancers as first and second primary cancers
od: Guoqiao Zheng, i dr.
Izdano: (2021-12-01)

Critical survival periods in prostate cancer in Sweden explored by conditional survival analysis
od: Kari Hemminki, i dr.
Izdano: (2024-04-01)

Survival, Incidence, and Mortality Trends in Female Cancers in the Nordic Countries
od: Filip Tichanek, i dr.
Izdano: (2023-01-01)

Survival in gastric and esophageal cancers in the Nordic countries through a half century
od: Kari Hemminki, i dr.
Izdano: (2023-05-01)

Long-term survival trends for primary liver and pancreatic cancers in the Nordic countries
od: Kari Hemminki, i dr.
Izdano: (2022-12-01)

Conditional survival in breast cancer up to 10 years in the Nordic countries
od: Frantisek Zitricky, i dr.
Izdano: (2023-09-01)

Survival trends in hematological malignancies in the Nordic countries through 50 years
od: Kari Hemminki, i dr.
Izdano: (2022-11-01)

Survival improvements in esophageal and gastric cancers in the Nordic countries favor younger patients
od: Kari Hemminki, i dr.
Izdano: (2024-08-01)

High familial risks in some rare cancers may pinpoint to hidden germline genetics: focus on esophageal, stomach, small intestinal, testis, thyroid and bone cancers
od: Kari Hemminki, i dr.
Izdano: (2025-02-01)

Survival in oral and pharyngeal cancers is catching up with laryngeal cancer in the NORDIC countries through a half century
od: Frantisek Zitricky, i dr.
Izdano: (2024-01-01)

Age-specific familial risks in cancer as clues to germline genetic and environmental causes: focus on colorectal, endometrial, prostate, kidney, breast and lung cancers
od: Kari Hemminki, i dr.
Izdano: (2025-02-01)

Incidence, mortality and survival in multiple myeloma compared to other hematopoietic neoplasms in Sweden up to year 2016
od: Kari Hemminki, i dr.
Izdano: (2021-08-01)

Incidence and survival in non-hereditary amyloidosis in Sweden
od: Hemminki Kari, i dr.
Izdano: (2012-11-01)

Familial risks in and between stone diseases: sialolithiasis, urolithiasis and cholelithiasis in the population of Sweden
od: Kari Hemminki, i dr.
Izdano: (2018-07-01)

Rate differences between first and second primary cancers may outline immune dysfunction as a key risk factor
od: Guoqiao Zheng, i dr.
Izdano: (2020-11-01)

Epidemiology of Amyloidosis and Genetic Pathways to Diagnosis and Typing
od: Kari Hemminki, i dr.
Izdano: (2021-07-01)

Family history of any cancer for childhood leukemia patients in Sweden
od: Xinjun Li, i dr.
Izdano: (2021-08-01)

Survival in Thyroid Cancer in Sweden From 1999 To 2018
od: Zitricky F, i dr.
Izdano: (2024-10-01)

Second cancers and causes of death in patients with testicular cancer in Sweden.
od: Luyao Zhang, i dr.
Izdano: (2019-01-01)

Comparison of survival of patients with metastases from known versus unknown primaries: survival in metastatic cancer
od: Riihimäki Matias, i dr.
Izdano: (2013-01-01)

Prostate cancer survivors: Risk and mortality in second primary cancers
od: Subhayan Chattopadhyay, i dr.
Izdano: (2018-11-01)

Surveillance Bias in Cancer Risk After Unrelated Medical Conditions: Example Urolithiasis
od: Kari Hemminki, i dr.
Izdano: (2017-08-01)

Survival in Lung Cancer in the Nordic Countries Through A Half Century
od: Tichanek F, i dr.
Izdano: (2023-05-01)

Survival in common cancers defined by risk and survival of family members
od: Jianguang Ji, i dr.
Izdano: (2011-10-01)

Familial risks between Graves disease and Hashimoto thyroiditis and other autoimmune diseases in the population of Sweden
od: Hauke Thomsen, i dr.
Izdano: (2020-01-01)

Second Primary Cancers After Kidney Cancers, and Kidney Cancers as Second Primary Cancers
od: Guoqiao Zheng, i dr.
Izdano: (2021-02-01)

Familial Associations of Colorectal Cancer with Other Cancers
od: Hongyao Yu, i dr.
Izdano: (2017-07-01)

Oncolytic viruses for cancer immunotherapy
od: Otto Hemminki, i dr.
Izdano: (2020-06-01)

The 'common disease-common variant' hypothesis and familial risks.
od: Kari Hemminki, i dr.
Izdano: (2008-01-01)

Oncolytic Immunotherapy: Where Are We Clinically?
od: Akseli Hemminki
Izdano: (2014-01-01)

Portrait of a Leader in Immunotherapeutics<subtitle>Oncolytic viruses for treatment of cancer</subtitle>
od: Akseli Hemminki
Izdano: (2012-08-01)

TILT Biotherapeutics
od: Akseli Hemminki
Izdano: (2017-05-01)

Treatment of Advanced Renal Cell Carcinoma: Immunotherapies Have Demonstrated Overall Survival Benefits While Targeted Therapies Have Not
od: Otto Hemminki, i dr.
Izdano: (2020-12-01)

Are population level familial risks and germline genetics meeting each other?
od: Kari Hemminki, i dr.
Izdano: (2023-03-01)